Problem: All of the following are true in regard to bone density measurement/ screening benefit for Medicare beneficiaries except: Group of answer choices All women deemed estrogen-deficient and at risk for osteoporosis are eligible Medicare Part B will cover the full cost of screening every six months, for the life of the individual, for all beneficiaries Men and women receiving glucocorticoid therapy for greater than 3 months are eligible for this screening benefit Men and women receiving osteoporosis drug therapy are eligible for this benefit